Description
BSE lists 4,477,612 new equity shares of Suven Life Sciences Ltd issued on a preferential basis via conversion of warrants, effective February 26, 2026.
Summary
BSE Notice No. 20260225-21 informs trading members that 4,477,612 new equity shares of Suven Life Sciences Ltd (Scrip Code: 530239) are listed and permitted to trade on BSE with effect from Thursday, February 26, 2026. These shares were issued to Non-Promoters on a preferential basis pursuant to conversion of warrants at an issue price of Rs. 134.00 per share (face value Rs. 1.00 + premium Rs. 133.00).
Key Points
- Company: Suven Life Sciences Ltd (Scrip Code: 530239)
- Number of shares listed: 4,477,612 equity shares
- Face value: Rs. 1.00 per share
- Issue price: Rs. 134.00 per share (premium of Rs. 133.00)
- Nature of issue: Preferential allotment to Non-Promoters via conversion of warrants
- Ranking: Pari-passu with existing equity shares
- Distinctive numbers: 227474208 to 231951819
- ISIN: INE495B01038
- Trading effective from: February 26, 2026
Regulatory Changes
No new regulatory changes introduced. This is a standard listing notification under BSE’s procedures for newly allotted securities.
Compliance Requirements
- Trading members are informed and permitted to trade these securities from February 26, 2026 onwards.
- The newly listed shares carry a lock-in restriction: all 4,477,612 shares (Dist. Nos. 227474208 to 231951819) are locked in until August 30, 2026.
- Market participants should note the lock-in period before executing any transactions in these shares on behalf of allottees.
Important Dates
| Event | Date |
|---|---|
| Date of Allotment | January 29, 2026 |
| BSE Notice Date | February 25, 2026 |
| Trading Commences | February 26, 2026 |
| Lock-in Expiry | August 30, 2026 |
Impact Assessment
The listing of approximately 4.48 million new equity shares expands the total share capital of Suven Life Sciences Ltd. Since these shares are issued to Non-Promoters at Rs. 134.00 per share and are subject to a lock-in until August 30, 2026, there is no immediate increase in freely tradable float. Post lock-in expiry in late August 2026, the additional supply could exert moderate selling pressure depending on prevailing market conditions. The preferential allotment indicates the company raised capital through warrant conversion, which may reflect positively on its funding activity.
Impact Justification
Routine preferential allotment listing following warrant conversion; introduces ~4.48 million new shares with a lock-in period, which could affect float and supply dynamics for Suven Life Sciences.